A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Amneal Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 548,975 shares of AMRX stock, worth $4.43 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
548,975
Previous 558,113 1.64%
Holding current value
$4.43 Million
Previous $3.54 Million 28.87%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$6.42 - $8.83 $58,665 - $80,688
-9,138 Reduced 1.64%
548,975 $4.57 Million
Q2 2024

Aug 09, 2024

BUY
$5.36 - $7.11 $132,279 - $175,467
24,679 Added 4.63%
558,113 $3.54 Million
Q1 2024

May 09, 2024

BUY
$5.24 - $6.34 $296,206 - $358,387
56,528 Added 11.85%
533,434 $3.23 Million
Q4 2023

Feb 09, 2024

SELL
$3.36 - $6.21 $51,737 - $95,621
-15,398 Reduced 3.13%
476,906 $2.89 Million
Q3 2023

Nov 13, 2023

BUY
$2.76 - $4.59 $295,568 - $491,543
107,090 Added 27.8%
492,304 $2.08 Million
Q2 2023

Aug 10, 2023

BUY
$1.33 - $3.1 $72,773 - $169,622
54,717 Added 16.56%
385,214 $1.19 Million
Q1 2023

May 09, 2023

BUY
$1.27 - $2.7 $122,402 - $260,226
96,380 Added 41.17%
330,497 $459,000
Q4 2022

Feb 10, 2023

BUY
$1.96 - $2.61 $157,636 - $209,914
80,427 Added 52.33%
234,117 $465,000
Q3 2022

Nov 10, 2022

BUY
$2.02 - $3.62 $310,453 - $556,357
153,690 New
153,690 $310,000
Q4 2020

Feb 16, 2021

SELL
$3.95 - $5.42 $71,155 - $97,635
-18,014 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$3.54 - $5.27 $994,927 - $1.48 Million
-281,053 Reduced 93.98%
18,014 $70,000
Q2 2020

Aug 13, 2020

BUY
$2.87 - $5.46 $335,147 - $637,596
116,776 Added 64.06%
299,067 $1.42 Million
Q1 2020

May 13, 2020

BUY
$2.46 - $5.35 $448,435 - $975,256
182,291 New
182,291 $634,000

Others Institutions Holding AMRX

About Amneal Pharmaceuticals, Inc.


  • Ticker AMRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 151,408,992
  • Market Cap $1.22B
  • Description
  • Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...
More about AMRX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.